Rock-Solid Triferic Heads Toward ODAC Review
This article was originally published in The Pink Sheet Daily
Executive Summary
Rockwell Medical Inc.’s ferric pyrophosphate seems poised to help firm’s emerging dialysis franchise if FDA is comfortable with an imbalance of deaths deemed not related to the drug seen in pivotal trials.
You may also be interested in...
Rockwell Sees Opportunity For Triferic In Cost-Sensitive CKD Market
Rockwell Medical has filed an NDA for the iron replacement therapy, which will be positioned as an alternative to I.V. iron during dialysis and could limit the need for erythropoietin-stimulating agents.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Rare Disease Roundtable: How Rare Is Too Rare?
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.